Brand ezetimibe runs roughly $400 to $500 per month while the generic costs about $8 to $30, often under $10 net. The highest-value lipid therapy is therefore among the least expensive drugs in the formulary. That gap matters more in 2026 because eligibility widened: the new US dyslipidemia guideline extends primary-prevention assessment to ages 30 through 79, replaces the Pooled Cohort Equations with PREVENT-ASCVD, and adds stage 3 or higher CKD and HIV to the conditions warranting statin therapy independent of calculated risk.
AAVBC's Lipid Medication Treatment Utilization Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering secondary and primary prevention indications, hypertriglyceridemia, contraindications and major precautions, drug and clinical interactions, PREVENT-ASCVD risk estimation and coronary artery calcium use, the stepwise LDL-lowering pathway, statin-associated symptom evaluation and rechallenge, pancreatitis prevention at severe triglyceride elevations, monitoring and criteria for safe maintenance, treatment-failure workup, cost-smart generic prescribing, and HEDIS statin measure alignment. Grounded in the 2026 US dyslipidemia guideline and current peer-reviewed literature, this guide supports consistent, individualized clinical decision-making, helping care teams reach lipid goals with the least expensive therapy that achieves them, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of lipid medication — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
Brand ezetimibe runs roughly $400 to $500 per month while the generic costs about $8 to $30, often under $10 net. The highest-value lipid therapy is therefore among the least expensive drugs in the formulary. That gap matters more in 2026 because eligibility widened: the new US dyslipidemia guideline extends primary-prevention assessment to ages 30 through 79, replaces the Pooled Cohort Equations with PREVENT-ASCVD, and adds stage 3 or higher CKD and HIV to the conditions warranting statin therapy independent of calculated risk.
AAVBC's Lipid Medication Treatment Utilization Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering secondary and primary prevention indications, hypertriglyceridemia, contraindications and major precautions, drug and clinical interactions, PREVENT-ASCVD risk estimation and coronary artery calcium use, the stepwise LDL-lowering pathway, statin-associated symptom evaluation and rechallenge, pancreatitis prevention at severe triglyceride elevations, monitoring and criteria for safe maintenance, treatment-failure workup, cost-smart generic prescribing, and HEDIS statin measure alignment. Grounded in the 2026 US dyslipidemia guideline and current peer-reviewed literature, this guide supports consistent, individualized clinical decision-making, helping care teams reach lipid goals with the least expensive therapy that achieves them, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of lipid medication — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
